Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 18Recruiting 5Unknown 4Terminated 4Active not recruiting 2Not yet recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 159Thoracic 18Genitourinary 17Dermatologic 15Gynecologic 14Head & Neck 13Breast 11Sarcoma 9Endocrine 4CNS 4NET 3Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Lymphoma 159Lymphoma, Non-Hodgkin 143Leukemia, Lymphocytic, Chronic, B-Cell 137Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Follicular 114Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Mantle-Cell 74Lymphoma, B-Cell 73Hodgkin Disease 66Multiple Myeloma 61Leukemia 58Burkitt Lymphoma 49Lymphoma, B-Cell, Marginal Zone 48Leukemia, Myeloid, Acute 48Recurrence 46Neoplasms 45Myelodysplastic Syndromes 43Hematologic Neoplasms 35Waldenstrom Macroglobulinemia 27Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Lymphoma, T-Cell 16Leukemia, Biphenotypic, Acute 16Leukemia, B-Cell 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Mycosis Fungoides 15Lymphoproliferative Disorders 15Myeloproliferative Disorders 14Lymphoma, T-Cell, Peripheral 14Lymphoma, T-Cell, Cutaneous 14Breast Neoplasms 14

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1dostarlimab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Hepatocellular × Lymphoid × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

Phase 1/2 Active not recruiting
83 enrolled
CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡